Zhitong Finance App News, on March 27, Yasheng Pharmaceutical-B (06855) announced its 2023 annual results: Yasheng Pharmaceuticals achieved total revenue of RMB 222 million during the reporting period. As Nellick, the core product of Yasheng Pharmaceutical, is included in the national medical insurance catalogue and approved for marketing for new indications, and by speeding up admission, patient accumulation, and extending the duration of medication, it is expected that more patients will benefit from Nellick's treatment plan, driving sales growth in 2024.
Financial reports show that while the commercial self-hematopoietic capacity continues to improve, Yasheng Pharmaceutical is rapidly advancing the patient-centered “global innovation” strategy, and has achieved landmark progress in clinical development and international layout. The global clinical layout is being promoted efficiently: the two core varieties, Nellick and the Bcl-2 inhibitor APG-2575, have obtained a total of 5 globally registered phase III clinical trial approvals, 2 of which have been approved by the US FDA to establish a moat in the field of hematologic oncology.
Dr. Yang Dajun, Chairman and CEO of Yasheng Pharmaceutical, said, “In the future, we will continue to strengthen the company's commercialization and innovative R&D capabilities to accelerate clinical development of the products under development on a global scale. We look forward to introducing innovative global drugs into the international market in the future, truly carrying out the mission of 'solving the unmet clinical needs of patients in China and the world', benefiting patients around the world and creating more value for society and shareholders.”